Motivan (Paroxetine)

Paroxetine, the active ingredient in Motivan, is a selective serotonin reuptake inhibitor (SSRI) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder and several anxiety‑related conditions in adult patients.

GNH USA supplies Motivan as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU quality standards and providing the product to hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery and regulatory documentation for each market, and we also offer technical support and product authentication services to our partners.

Paroxetine is an SSRI antidepressant that modulates serotonergic pathways and is used in several psychiatric conditions.

Major depressive disorder: reduces depressive symptoms and improves mood in adults. Generalized anxiety disorder: alleviates excessive worry and tension. Panic disorder: decreases frequency and severity of panic attacks. Obsessive‑compulsive disorder: lessens intrusive thoughts and compulsive behaviors. Social anxiety disorder: reduces fear of social situations and improves functioning. Post‑traumatic stress disorder: mitigates re‑experiencing symptoms and hyperarousal.

Paroxetine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: upset stomach often occurring at treatment initiation. - Headache: mild to moderate cranial pain. - Dry mouth: reduced salivation leading to discomfort. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Serotonin syndrome: potentially life‑threatening condition with agitation, hyperthermia, and neuromuscular abnormalities. - Suicidal thoughts: increased risk especially in young adults during early therapy. - Severe allergic reaction: rash, swelling, or anaphylaxis requiring immediate medical attention.

When prescribing Paroxetine, several precautions should be observed to ensure safe use. - Assess for suicidal ideation: monitor patients closely, particularly during the first weeks of treatment. - Avoid abrupt discontinuation: taper the dose under medical supervision to reduce withdrawal symptoms. - Use caution in hepatic impairment: dose adjustment may be necessary due to altered metabolism. - Review concomitant serotonergic agents: increased risk of serotonin syndrome requires careful assessment. - Pregnancy and lactation: potential risks are unknown; weigh benefits against possible fetal or infant exposure. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Paroxetine interacts with several medications; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can precipitate serotonin syndrome. - Pimozide: may cause QT interval prolongation and cardiac arrhythmias. - Thioridazine: increased risk of cardiac toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may elevate bleeding risk. - Warfarin: enhanced anticoagulant effect, requiring INR monitoring. - Triptans: potential additive serotonergic effect, monitor for serotonin syndrome.